Rossmore Private Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Rossmore Private Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-461	Closed	-$292K	–	262
2025 Q1	$292K	Buy	461 +1	+0.2%	+$688	0.04%	214
2024 Q4	$328K	Hold	460	–	–	0.04%	199
2024 Q3	$484K	Hold	460	–	–	0.06%	171
2024 Q2	$483K	Hold	460	–	–	0.06%	168
2024 Q1	$443K	Hold	460	–	–	0.06%	176
2023 Q4	$404K	Hold	460	–	–	0.06%	179
2023 Q3	$379K	Hold	460	–	–	0.06%	174
2023 Q2	$331K	Hold	460	–	–	0.05%	188
2023 Q1	$378K	Hold	460	–	–	0.06%	173
2022 Q4	$332K	Hold	460	–	–	0.05%	182
2022 Q3	$317K	Hold	460	–	–	0.06%	183
2022 Q2	$272K	Sell	460 -200	-30%	-$130K	0.05%	193
2022 Q1	$461K	Hold	660	–	–	0.07%	162
2021 Q4	$417K	Hold	660	–	–	0.07%	172
2021 Q3	$399K	Hold	660	–	–	0.07%	168
2021 Q2	$369K	Hold	660	–	–	0.06%	173
2021 Q1	$312K	Buy	660 +200	+43%	+$97.4K	0.06%	172
2020 Q4	$222K	Hold	460	–	–	0.05%	189
2020 Q3	$257K	Hold	460	–	–	0.06%	163
2020 Q2	$287K	Hold	460	–	–	0.08%	147
2020 Q1	$225K	Buy	+460	New	+$190K	0.08%	136

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Rossmore Private Capital's REGN Position: Q2 2025 in Review

Rossmore Private Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 461 shares — an estimated $292K sold.

Rossmore Private Capital first reported a position in REGN in Q1 2020 and held it in 21 quarters. The position peaked at $484K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Rossmore Private Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Rossmore Private Capital sold 461 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $292K.
Rossmore Private Capital first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 21 quarters.
Rossmore Private Capital's Regeneron Pharmaceuticals position peaked at $484K in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Rossmore Private Capital's 13F filing for Q2 2025, filed 7 Aug 2025.